J Androl 2012;33(2):170-175
When appropriate, we support patients in transitioning to the lowest level of intervention necessary to maintain their results , rather than escalating care indefinitely
With TRIUMPH-4 (December 2025, 28.7% weight loss), TRIUMPH-1 (May 2026, 28.3% in 2,339 patients), and now TRANSCEND-T2D-1 (June 2026, the first diabetes-specific Phase 3 readout) all confirmed, this investigational medication is rapidly approaching regulatory review
CrossRef Impact of glucagonlike peptide1 receptor agonists on diabetic retinopathy: A metaanalysis of clinical studies emphasising retinal changes as a primary outcome Ishani Kapoor, Swara M
SLC6A14 exhibits elevated expression in CRC [57], estrogen receptor positive (ER +) breast cancer [58], and pancreatic cancer [59], concomitant with their proliferative capacity
These effects are likely mediated by Wnt/-catenin signaling, which is activated via increased -catenin, proven by Li et al